Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,370.00
(
-0.75%
)
Dow Jones
49,141.93
(
-0.34%
)
Brent Oil
104.50
(
0.08%
)
Bitcoin
76,386.96
(
0.05%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122898
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 06/21/2018 8:50:00 AM

Thursday, June 21, 2018 8:50:00 AM

Post# of 257458
AVRO IPOs 6.03M* shares @$19.00:

https://finance.yahoo.com/news/avrobio-inc-announces-pricing-initial-004240194.html

AVROBIO, Inc. is a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose.

AVROBIO is initially targeting Fabry disease, Gaucher disease, Pompe disease and cystinosis with its ex vivo gene therapy approach. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today